Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10955646 | PMC |
| http://dx.doi.org/10.1182/bloodadvances.2023012478 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Acute graft-versus-host disease therapy: Which third line treatment after steroids and ruxolitinib? (SFGM-TC)].
Bull Cancer
September 2025
Service d'hématologie, département d'oncologie, hôpitaux universitaire de Genève (HUG), faculté de médecine, université de Genève, Genève, Suisse. Electronic address:
Acute graft-versus-host disease (GVHDa) is one of the leading causes of morbidity and mortality after allogeneic hematopoietic stem cell transplant (HSCT) patients. While the first-line consensus treatment has been based on systemic corticosteroid therapy for many years, ruxolitinib has recently been approved and has become the standard second-line treatment. Nevertheless, the effectiveness of ruxolitinib remains limited to 40 % of cortico-resistant patients, raising the crucial question of selecting a third-line treatment.
View Article and Find Full Text PDFA cohort of allogeneic hematopoietic stem cell transplantation for pediatric rare diseases (allo-HSCT-PRD): design and preliminary results.
Ann Hematol
September 2025
Department of Hematology and Oncology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Rare diseases in children have attracted widespread attention worldwide due to their rarity and difficulty in diagnosis and treatment. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is emerging as a promising and curable therapy for multiple rare diseases. However, rare disease research in China is relatively backward, prompting us to construct the first cohort of allo-HSCT for pediatric rare diseases (allo-HSCT-PRD) involving those who underwent allo-HSCT at the Children's Hospital of Fudan University from 1 January 2014 to 31 October 2024.
View Article and Find Full Text PDFAcute Respiratory Distress Syndrome Phenotypes After Stem Cell Transplantation: A Latent Class Analysis.
Crit Care Explor
September 2025
Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.
Objective: To identify distinct phenotypes of acute respiratory distress syndrome (ARDS) developing after hematopoietic cell transplantation (HCT), using routinely available clinical data at ICU admission.
Design: Multicenter retrospective cohort study using latent class analysis.
Setting: ICUs across three Mayo Clinic campuses (Minnesota, Florida, and Arizona).
The Clinical Utility of Real-Time Patient Reported Outcomes in Cell Therapy Recipients.
Transplant Cell Ther
September 2025
The Dartmouth Institute for Health Policy & Clinical Practice; Geisel School of Medicine at Dartmouth, Level 5, Williamson Building, One Medical Center Drive, Lebanon, NH, 03756.
Background: The use of patient-reported outcome measures (PROMs) can improve a patient's clinical course by decreasing the incidence and severity of both physical and emotional treatment-related toxicities, uncover unmet patient needs and assist in patients' shared decision-making.
Objectives: The objective of this study was to examine the feasibility and utility of using electronically captured "real time" agenda-setting questions and PROMs at the time of the patient's clinic visit.
Study Design: We designed a prospective observational study that employed a pre-visit questionnaire (PVQ) that included agenda-setting questions and the PROMIS-29 survey, with results incorporated into a clinical decision support dashboard embedded within the patients' electronic medical record (EMR).
Acute myeloid leukemia: a comprehensive update.
Curr Opin Hematol
August 2025
Hematopoietic Stem Cell Transplantation Program. Hematology Department Pontificia Universidad Católica de Chile Red de Salud Christus UC.
Purpose Of Review: Acute myeloid leukemia (AML) is a biologically diverse disease that has undergone significant transformation in recent years. The rapid pace of discovery in molecular genetics, disease classification, and therapeutic development has reshaped how we approach diagnosis and treatment. This review aims to provide a timely and relevant synthesis of these advances, offering clinicians and researchers an updated perspective on AML as of 2025.
View Article and Find Full Text PDF